Thymic epithelial neoplasm
MONDO:0018079An epithelial neoplasm that affects the thymus gland. This category includes thymomas and carcinomas.
Also known as: TEN, Thymus epithelial neoplasm, Thymus epithelial tumor, Thymus epithelial tumour, epithelial neoplasm of Thymus, epithelial neoplasm of the Thymus, epithelial tumor of Thymus, epithelial tumor of the Thymus
1628 clinical trials for this condition and its sub-types, 14 tagged with Thymic epithelial neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thymic epithelial neoplasm
-
Thymoma 44 trials
8 sub-types
- Invasive malignant thymoma 4 trials
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Combined thymoma 0 trials
- Encapsulated thymoma 0 trials
- Noninvasive malignant thymoma 0 trials
- Thymoma type A 0 trials Sub-types →
- Thymoma type AB 0 trials Sub-types →
- Thymoma, familial 0 trials
-
Thymic carcinoma 41 trials · 44 incl. sub-types
9 sub-types
- Invasive malignant thymoma 4 trials
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Lymphoepithelioma-like thymic carcinoma 0 trials
- Malignant type AB thymoma 0 trials
- Thymic sarcomatoid carcinoma 0 trials
- Thymic undifferentiated carcinoma 0 trials
- Thymus clear cell carcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Thymus squamous cell carcinoma 0 trials Sub-types →
Most studied deeper sub-types
-
Experimental drug targets rare thymus cancers after chemotherapy fails
Disease control OngoingThis phase II trial tests bintrafusp alfa (M7824) in 9 adults with thymoma or thymic carcinoma that returned after platinum-based chemotherapy. Participants receive the drug intravenously every two weeks until their disease worsens or side effects become intolerable. The study ai…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New immunotherapy combo targets rare cancers left behind by progress
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Thymoma treatment trial pulled before starting
Knowledge-focused CancelledThis study was designed to see if adding chemotherapy to radiation therapy after incomplete surgery for thymoma or thymic carcinoma could improve survival. It planned to enroll adults aged 18-75 who had incomplete tumor removal. However, the trial was withdrawn before any partici…
Phase 3 • Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC